But first, some of what was going on at St. Pete’s, this afternoon:
I love crowd-sourced knowledge. So efficient!
Here is exhibit A — from my readership. Do read it all.
. . . .Anonymous said. . .
I don’t believe that Stallergenes has a ragweed product at the FDA right now. Checking the FDA site only turns up a grass tablet.
Yes, the current Stallergenes approved product for SLIT is a multi-perennial grass extracts (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergenic Extracts).
However, these grasses share immuno-crossreactivity. It is not clear that you need to do all or that 1 will cover for all.
Either way, neither cover ragweed. Hence, the development of the Merck product.
Both companies are working on house dust mite therapies. And Stallergenes is also pursuing tree pollen.
April 18, 2014 at 1:56 PM
Condor said. . .
I now bow before you!
Fabulous! Thank you Anon.!
Love my readership. . . .
This is likely a new post, when I catch a breather — likely Saturday. . .
Even so, I stick by the idea that Ragwitek will max out around $250M a year in peak sales. . . as there are already injections on market.
Just my gut — but as I was wrong about Stallergenes — I could be wrong here too. . . So there is no sub-lingual ragweed product approved anywhere in the world? Wild!
Thank you so much — as ever,
April 18, 2014 at 2:21 PM. . . .
Here is a link to the remainder of this comment thread. . . as it evolves. Peace – during this season of renewal, repair and rebirth — to all.